BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Vusolimogene oderparepvec (Tudriqev) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Vusolimogene oderparepvec (Tudriqev)\, fr
 om ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06216938-2713@assetmemo.bio
DTSTAMP:20261121T004537Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Vusolimogene oderparepvec (Tudriqev): Phase 1 readout est. (NCT0621
 6938)
DESCRIPTION:Vusolimogene oderparepvec (Tudriqev)\, phase 1\, Melanoma.\nStu
 dy: RP1 in Primary Melanoma to Reduce the Risk of Sentinel Lymph Node Meta
 stasis\nEstimated primary completion: 31 March 2028. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/vusolimogene-oderparepvec-tudriqev#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT06216938
URL:https://assetmemo.bio/drug/vusolimogene-oderparepvec-tudriqev#upcoming-
 events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03767348-2713@assetmemo.bio
DTSTAMP:20261121T004537Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Vusolimogene oderparepvec (Tudriqev): Phase 2 readout est. (NCT0376
 7348)
DESCRIPTION:Vusolimogene oderparepvec (Tudriqev)\, phase 2\, Non-Small Cell
  Lung Cancer.\nStudy: Study of RP1 Monotherapy and RP1 in Combination With
  Nivolumab (IGNYTE)\nEstimated primary completion: June 2028. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/vusolimogene-oderparepvec-tudriqe
 v#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT03
 767348
URL:https://assetmemo.bio/drug/vusolimogene-oderparepvec-tudriqev#upcoming-
 events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04349436-2713@assetmemo.bio
DTSTAMP:20261121T004537Z
DTSTART;VALUE=DATE:20290731
DTEND;VALUE=DATE:20290801
SUMMARY:Vusolimogene oderparepvec (Tudriqev): Phase 1/2 readout est. (NCT04
 349436)
DESCRIPTION:Vusolimogene oderparepvec (Tudriqev)\, phase 1/2.\nStudy: Study
  to Investigate the Efficacy and Safety of RP1 in Adult Patients With Orga
 n Transplants and Advanced Skin Malignancies\nEstimated primary completion
 : July 2029. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/vusolimo
 gene-oderparepvec-tudriqev#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT04349436
URL:https://assetmemo.bio/drug/vusolimogene-oderparepvec-tudriqev#upcoming-
 events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06898970-2713@assetmemo.bio
DTSTAMP:20261121T004537Z
DTSTART;VALUE=DATE:20291031
DTEND;VALUE=DATE:20291101
SUMMARY:Vusolimogene oderparepvec (Tudriqev): Phase 2 readout est. (NCT0689
 8970)
DESCRIPTION:Vusolimogene oderparepvec (Tudriqev)\, phase 2.\nStudy: Intratu
 moral Vusolimogene Oderparepvec (VO) in Combination With Pembrolizumab for
  Angiosarcoma\nEstimated primary completion: 31 October 2029. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/vusolimogene-oderparepvec-tudriqe
 v#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06
 898970
URL:https://assetmemo.bio/drug/vusolimogene-oderparepvec-tudriqev#upcoming-
 events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
